Clinical trial
Bevacizumab (Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear…
NCT00323739 · SCRI Development Innovations, LLC, Other · Completed
Key facts
| NCT number | NCT00323739 |
|---|---|
| Title | Bevacizumab (Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal Carcinoma |
| Official title | Phase II Trial of Bevacizumab(Avastin) and RAD001(Everolimus)in the Treatment of Patients With Advanced Clear Cell Renal Carcinoma |
| Lead sponsor | SCRI Development Innovations, LLC, Other |
| Collaborators | Genentech, Inc. Industry Novartis |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Kidney Cancer |
| Intervention type | Drug |
| Interventions | bevacizumab, RAD001 |
| Enrollment | 80 |
| Start date | May 1, 2006 |
| Primary completion | Nov 1, 2008 |
| Completion | Mar 1, 2011 |
| First posted | May 9, 2006 |
| Last update posted | Jul 26, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: